Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection
Intarcia’s troubled late-stage efforts to revolutionize the way diabetes is treated has run into a fresh round of setbacks.
The Boston-based biotech — a private company once valued at $3.5 billion — confirmed to Endpoints News late Friday night that the company has cut 60 staffers and been hit by a clinical hold from the FDA.
Those setbacks come four months after the FDA rejected Intarcia’s implanted diabetes drug/device, which is designed to deliver stable doses of exenatide with twice-yearly tune-ups. Intarcia CEO Kurt Graves has long championed the device as a certain blockbuster, earning kudos and $600 million in Series EE investment capital along the way.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.